HF Advisory Group LLC Has $1.20 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

HF Advisory Group LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 14,827 shares of the biopharmaceutical company’s stock after purchasing an additional 308 shares during the period. HF Advisory Group LLC’s holdings in Gilead Sciences were worth $1,201,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Cetera Investment Advisers increased its holdings in shares of Gilead Sciences by 9.2% during the first quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after purchasing an additional 4,877 shares during the period. Baird Financial Group Inc. increased its stake in Gilead Sciences by 3.9% in the first quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 16,643 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in Gilead Sciences by 44.3% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after acquiring an additional 2,654 shares during the last quarter. Donaldson Capital Management LLC increased its stake in Gilead Sciences by 12.5% in the first quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 641 shares during the last quarter. Finally, Ergoteles LLC bought a new position in Gilead Sciences in the first quarter valued at approximately $2,304,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. Mizuho decreased their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Wells Fargo & Company decreased their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Cantor Fitzgerald decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Finally, Barclays decreased their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $84.71.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.5 %

Shares of NASDAQ GILD traded down $0.34 during trading on Thursday, hitting $66.59. 1,092,068 shares of the company traded hands, compared to its average volume of 7,234,129. The business’s fifty day moving average is $72.25 and its 200 day moving average is $76.66. Gilead Sciences, Inc. has a fifty-two week low of $66.15 and a fifty-two week high of $87.86. The firm has a market capitalization of $82.91 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 0.92 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the prior year, the company posted $1.67 EPS. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.63%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.